MEDCO/PAID HAS HIGHEST USE OF LESCOL AMONG TOP RETAIL PBMs, IMS DATA SHOW; GENERIC PENETRATION OF CIMETIDINE IS SIMILAR IN CASH AND MANAGED CARE MARKETS
Value Health's promotion of Sandoz' HMG-CoA reductase inhibitor Lescol following the drug's April 1994 launch did not result in increased use of Lescol on ValueRx formularies compared to other pharmacy benefit management companies, IMS market share data for 1994 show.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth